

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE - Cardboard box**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Bupaq Multidose 0.3 mg/ml solution for injection

Buprenorphine

**2. STATEMENT OF ACTIVE SUBSTANCES**

Buprenorphine (as hydrochloride) 0.3 mg/ml

**3. PACKAGE SIZE**

10 ml

5 x 10 ml

10 x 10 ml

**4. TARGET SPECIES**

Dogs and cats

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

i.m. or i.v. use.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached, use within 28 days.

**9. SPECIAL STORAGE PRECAUTIONS**

Protect from light.

Do not refrigerate or freeze.

**10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"**

Read the package leaflet before use.

**11. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

VetViva Richter (logo) 

**14. MARKETING AUTHORISATION NUMBERS**

Vm 57446/4001

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING  
UNITS – 10 ml amber glass vial type I with brombutyl rubber stopper and alu-  
caps**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Bupaq Multidose



Dogs, cats

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Buprenorphine 0.3 mg/ml

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached, use by...

10 ml

VetViva Richter (logo)

## **PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

### **PACKAGE LEAFLET**

#### **1. Name of the veterinary medicinal product**

Bupaq Multidose 0.3 mg/ml solution for injection for dogs and cats

#### **2. Composition**

Each ml contains:

##### **Active substances:**

Buprenorphine (as hydrochloride) 0.3 mg

##### **Excipients:**

Chlorocresol 1.35 mg

Clear, colourless to almost colourless solution.

#### **3. Target species**

Dogs and cats

#### **4. Indications for use**

##### Dogs

Post-operative analgesia.

Potentialiation of the sedative effects of centrally-acting agents.

##### Cats

Post-operative analgesia.

#### **5. Contraindications**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients. Do not administer by the intrathecal or peridural route. Do not use pre-operatively for Caesarian section (see section "Pregnancy").

#### **6. Special warnings**

##### Special precautions for safe use in the target species:

Use of the veterinary medicinal product in the below circumstances should only be in accordance with the benefit-risk assessment by the responsible veterinarian.

Buprenorphine may cause respiratory depression and as with other opioid drugs, care should be taken when treating animals with impaired respiratory function or animals that are receiving drugs that can cause respiratory depression.

In case of renal, cardiac or hepatic dysfunction or shock, there may be greater risk associated with the use of the veterinary medicinal product.

Safety has not been fully evaluated in clinically compromised cats.

Buprenorphine should be used with caution in animals with impaired liver function, especially biliary tract disease, as the substance is metabolised by the liver and its intensity and duration of action may be affected in such animals.

The safety of buprenorphine has not been demonstrated in animals less than 7 weeks of age.

Repeat administration earlier than the recommended repeat interval suggested in section "Dosage for each species" is not recommended.

Long-term safety of buprenorphine in cats has not been investigated beyond 5 consecutive days of administration.

The effect of an opioid on head injury is dependent on the type and severity of the injury and the respiratory support supplied.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands/affected area thoroughly after any accidental spillage.

As buprenorphine has opioid-like activity, care should be taken to avoid self-injection. In case of accidental self-injection or ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Naloxone should be available in case of accidental parenteral exposure.

In case of accidental eye contamination or spillage onto skin, wash thoroughly with cold running water. Seek medical advice if irritation persists.

#### Pregnancy:

Laboratory studies in rats have not produced any evidence of a teratogenic effect. However, these studies have shown post-implantation losses and early foetal deaths. These may have resulted from a reduction in parental body condition during gestation and in post-natal care owing to sedation of the mothers.

As reproductive toxicity studies have not been conducted in the target species, use only according to the benefit-risk assessment by the responsible veterinarian.

The veterinary medicinal product should not be used pre-operatively in cases of Caesarean section, due to the risk of respiratory depression in the offspring periparturiently, and should only be used post-operatively with special care (see below section "Lactation").

#### Lactation:

Studies in lactating rats have shown that, after intramuscular administration of buprenorphine, concentrations of unchanged buprenorphine in the milk equalled or exceeded that in the plasma. As it is likely that buprenorphine will be excreted in the milk of other species, use is not recommended during lactation. Use only in accordance with the benefit-risk assessment by the responsible veterinarian.

#### Interaction with other medicinal products and other forms of interaction:

Buprenorphine may cause some drowsiness, which may be potentiated by other centrally acting agents, including tranquillisers, sedatives and hypnotics.

There is evidence in humans to indicate that therapeutic doses of buprenorphine do not reduce the analgesic efficacy of standard doses of an opioid agonist, and that when buprenorphine is employed within the normal therapeutic range, standard doses of opioid agonist may be administered before the effects of the former have ended without compromising analgesia. However, it is recommended that buprenorphine is not used in conjunction with morphine or other opioid-type

analgesics, e.g. etorphine, fentanyl, pethidine, methadone, papaveretum or butorphanol.

Buprenorphine has been used with acepromazine, alphaxalone/alphadalone, atropine, dexmedetomidine, halothane, isoflurane, ketamine, medetomidine, propofol, sevoflurane, thiopental and xylazine. When used in combination with sedatives, depressive effects on heart rate and respiration may be augmented.

#### Overdose:

In cases of overdosage, supportive measures should be instituted, and, if appropriate, naloxone or respiratory stimulants may be used.

When administered at overdose to dogs, buprenorphine may cause lethargy. At very high doses, bradycardia and miosis may be observed.

Naloxone may be of benefit in reversing reduced respiratory rate and respiratory stimulants such as Doxapram are also effective in man. Because of the prolonged duration of effect of buprenorphine in comparison to such drugs, they may need to be administered repeatedly or by continuous infusion. Volunteer studies in man have indicated that opiate antagonists may not fully reverse the effects of buprenorphine. In toxicological studies of buprenorphine hydrochloride in dogs, biliary hyperplasia was observed after oral administration for one year at dose levels of 3.5 mg/kg/day and above. Biliary hyperplasia was not observed following daily intramuscular injection of dose levels up to 2.5 mg/kg/day for 3 months. This is well in excess of any clinical dose regimen in the dog.

#### <Special restrictions for use and special conditions for use:>

#### Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **7. Adverse events**

#### **Dogs:**

Rare (1 to 10 animals / 10 000 animals treated):

Hypertension (high blood pressure), Tachycardia (rapid heart rate), Sedation<sup>1</sup>.

<sup>1</sup> When used to provide analgesia. May occur at dose levels higher than those recommended.

Very rare (<1 animal / 10 000 animals treated, including isolated reports):

Injection site reaction<sup>2</sup>, Injection site pain<sup>2</sup>, Vocalisation<sup>3</sup>.

<sup>2</sup> With local discomfort. The effect is normally temporary.

<sup>3</sup> Caused by injection site pain.

Undetermined frequency (cannot be estimated from the available data):

Hypersalivation (increased salivation), Bradycardia (slow heart rate), Hypothermia (low body temperature), Dehydration, Agitation, Miosis (constricted pupils), Respiratory depression.

**Cats:**

Common (1 to 10 animals / 100 animals treated):

Mydriasis<sup>1</sup> (dilated pupils), Behavioural disorder<sup>1,2</sup>.

<sup>1</sup> Will usually resolve within 24 hours.

<sup>2</sup> Signs of euphoria (excessive purring, pacing, rubbing).

Rare (1 to 10 animals / 10 000 animals treated):

Sedation<sup>3</sup>.

<sup>3</sup> When used to provide analgesia. May occur at dose levels higher than those recommended.

Very rare (<1 animal / 10 000 animals treated, including isolated reports):

Injection site reaction<sup>4</sup>, Injection site pain<sup>4</sup>, Vocalisation<sup>5</sup>.

<sup>4</sup> With local discomfort. The effect is normally temporary.

<sup>5</sup> Caused by injection site pain.

Undetermined frequency (cannot be estimated from the available data):

Respiratory depression.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: [adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

**8. Dosage for each species, routes and method of administration**

Intramuscular (i.m.) or intravenous (i.v.) use.

To ensure a correct dosage, body weight should be determined as accurately as possible. The use of suitably calibrated measuring equipment is recommended.

**Dogs: Post-operative analgesia, potentiation of the sedation**

**Cats: Post-operative analgesia**

10 - 20 micrograms of buprenorphine hydrochloride per kg bodyweight (i.e. 0.3 - 0.6 ml of the veterinary medicinal product per 10 kg).

**For further pain relief the dose may be repeated if necessary:**

Dogs: either after 3 - 4 hours with 10 micrograms of buprenorphine hydrochloride per kg bodyweight.

or after 5 - 6 hours with 20 micrograms of buprenorphine hydrochloride per kg bodyweight.

Cats: Once, after 1 - 2 hours with 10 - 20 micrograms of buprenorphine hydrochloride per kg bodyweight.

The rubber stopper can be punctured a maximum of 25 times.

**9. Advice on correct administration**

While sedative effects are present by 15 minutes after administration, analgesic activity becomes apparent after approximately 30 minutes. To ensure that analgesia is present during surgery and immediately on recovery, the veterinary medicinal product should be administered preoperatively as part of premedication.

When administered for potentiation of sedation or as part of premedication, the dose of other centrally-acting agents, such as acepromazine or medetomidine, should be reduced. The reduction will depend on the degree of sedation required, the individual animal, the type of other agents included in premedication and how anaesthesia is to be induced and maintained. It may also be possible to reduce the amount of inhalational anaesthetic used.

Animals administered opioids possessing sedative and analgesic properties may show variable responses. Therefore, the response of individual animals should be monitored, and subsequent doses should be adjusted accordingly. In some cases, repeat doses may fail to provide additional analgesia. In these cases, consideration should be given to using a suitable injectable NSAID.

**10. Withdrawal periods**

Not applicable.

**11. Special storage precautions**

Keep out of the sight and reach of children.

Keep the vial in the outer carton in order to protect from light.

Do not refrigerate or freeze.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and carton after "Exp.". The expiry date refers to the last day of that month.

Shelf-life after first opening the immediate packaging: 28 days

**12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

### **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

### **14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES**

Vm 57446/4001

Pack sizes:

10 ml, 5 x 10 ml, 10 x 10 ml.

Not all pack sizes may be marketed.

### **15. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

### **16. Contact details**

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse events:

VetViva Richter GmbH

Durisolstrasse 14

4600 Wels

Austria

Tel: +43 (0)664 8455326

E-mail: [adverse.events@vetviva.com](mailto:adverse.events@vetviva.com)

### **17. Other information**

POM-V
-------

*Gavin Hall*  
Approved: 10 September 2025